Abstracts tagged "Colchicine"

Abstract Number: 3072 • 2016 ACR/ARHP Annual Meeting
Increased Platelet Reactivity in Gout: Relationship to Tophus Burden and Colchicine Use
Richard Conway¹, Claire-Louise Murphy², Anne Madigan³, Patricia Kavanagh⁴, Liz Geraghty³, Niamh Redmond⁵, Laura Helbert⁶, John J. Carey⁷, Eimear Dunne⁸, Dermot Kenny⁸ and Geraldine M. McCarthy⁹, ¹CARD Newman Research Fellow, University College Dublin, Dublin, Ireland, ²Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ³Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ⁴Rheumatology Department, Mater Public Hospital, Dublin 7, Ireland, ⁵UCD Clinical Research Centre, Dublin, Ireland, ⁶Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ⁷Rheumatology, Galway University Hospitals, Galway, Ireland, ⁸Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, ⁹Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland
Background/Purpose: Patients with gout have an increased risk of cardiovascular events. The presence of tophi is associated with enhanced cardiovascular risk. Increased platelet reactivity is…
Abstract Number: 261 • 2015 ACR/ARHP Annual Meeting
Anakinra Treatment in Patients with Familial Mediterranean Fever: A Single-Center Experience
Serdal Ugurlu¹, Bilgesu Ergezen² and Huri Ozdogan², ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Turkey, Istanbul, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: To review the patients followed in our center with FMF who received anakinra, an anti IL-1 receptor antagonist, because of insufficient colchicine response. Methods: FMF…
Abstract Number: 941 • 2015 ACR/ARHP Annual Meeting
Relationship Between Colchine Plasma Level and Frequency of Familial Mediterranean Fever Attacks
Fadime Canbolat¹, Gulsen Ozen², Selma Ozilhan¹, Samet Gulturk³, Ayse Ozcetin⁴, Ali Ugur Unal², Nevsun Inanc², Pamir Atagunduz², Haner Direskeneli² and Tuncel Ozden¹, ¹Department of Pharmacology, Uskudar University Pharmacogenetic Laboratory, Istanbul, Turkey, ²Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ³Department of Molecular Biology and Genetics, Uskudar University, Istanbul, Turkey, ⁴Department of Neuroscience, Uskudar University, Istanbul, Turkey
Background/Purpose: Colchicine is the mainstay of Familial Mediterranean Fever (FMF) treatment that reduces the frequency of attacks and prevents amyloidosis in the majority of patients. Colchicine,…
Abstract Number: 2343 • 2015 ACR/ARHP Annual Meeting
Impact of Colchicine Use on the Development of Incident Coronary Artery Disease
Susanna Jeurling¹, Daria Crittenden², Mark C. Fisher³, Binita Shah⁴, Steven P. Sedlis⁴, Craig T. Tenner⁵, Svetlana Krasnokutsky Samuels⁶ and Michael H. Pillinger⁷, ¹Division of Rheumatology, NYU School of Medicine, New York, NY, ²Rheumatology, NYU-HJD, New York, NY, ³Rheumatology, New York Univ-HJD, New York, NY, ⁴NYU School of Medicine, Division of Cardiology, New York, NY, ⁵Medicine, NYU School of Medicine, New York, NY, ⁶NYU School of Medicine, Division of Rheumatology, New York, NY, ⁷Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Patients with gout experience both inflammation and increased risk of cardiovascular disease (CVD). Studies suggest that colchicine reduces myocardial infarction (MI) risk, but whether…
Abstract Number: 2114 • 2014 ACR/ARHP Annual Meeting
Comorbidity Characteristics of Patients Starting First-Line Acute Gout Agents – Colchicine, NSAID, and Corticosteroids
Alfonso Perez¹, Robert Jackson², Jiao Yang³, Aki Shiozawa⁴, Shawn Yu⁴, Yimin Qin¹, Huifang Liang⁵ and Hyon K. Choi⁶, ¹Global Clinical Science, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ²Global Medical Office, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ³Analytical Science, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ⁴Global Outcomes and Epidemiology Research, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ⁵Pharmacovigilance, Takeda Pharmaceuticals International, Inc, Deerfield, IL, ⁶Boston University School of Medicine, Boston, MA
Comorbidity Characteristics of Patients Starting First-Line Acute Gout Agents - Colchicine, NSAID, and CorticosteroidsBackground/Purpose: There is a remarkable, increasing disease burden of gout and its…
Abstract Number: 47 • 2014 ACR/ARHP Annual Meeting
The Risk of Aplastic Anemia and Pancytopenia with Colchicine: A Retrospective Study of Integrated Health System Database
Jasvinder A. Singh¹, Shuo Yang² and Jeff Foster³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose Colchicine is a commonly used medication, sometime associated with bone marrow toxicity. The objective of this study was to examine the risk of severe…
Abstract Number: 1992 • 2013 ACR/ARHP Annual Meeting
Trends In Outpatient Treatment Of Gout In The US: From 1993 To 2009
Eswar Krishnan and Linjun Chen, Medicine, Stanford University, Palo Alto, CA
Background/Purpose: Gouty arthritis (gout) is primarily managed in the community by primary care providers. Relatively little is known about the treatment patterns as well as…
Abstract Number: 1986 • 2013 ACR/ARHP Annual Meeting
Colchicine Use and The Risk Of Myocardial Infarction Among Gout Patients: Results From a Community-Based, Informatics-Driven Retrospective Cohort Study
Daria B. Crittenden¹, Binita Shah², Steven P. Sedlis², Christopher J. Swearingen³, Eric S. Wagner⁴, Yvette M. Henry⁴, Peter B. Berger⁴, Bruce N. Cronstein¹ and Michael H. Pillinger⁵, ¹Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY, ²NYU School of Medicine, Division of Cardiology, New York, NY, ³Pediatric Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, ⁴Geisinger Health System, Cardiovascular Center for Clinical Research, Danville, PA, ⁵NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Gout patients have an increased risk of myocardial infarction (MI). Since atherosclerosis and plaque rupture are inflammatory processes, anti-inflammatory gout medications might also reduce…
Abstract Number: 1179 • 2013 ACR/ARHP Annual Meeting
Colchicine Use and The Risk Of Myocardial Infarction Among Gout Patients: Interim Results From a VA Retrospective Cohort Study
Daria B. Crittenden¹, Jessica N. Kimmel¹, Virginia C. Pike¹, Daniel Diaz¹, Avni Shah², Cilian J. White¹, Michael DeBerardine², Grace Kim², Binita Shah³, Christopher J. Swearingen⁴, Jeffrey D. Greenberg⁵, Steven P. Sedlis³, Craig T. Tenner⁶, Bruce N. Cronstein¹ and Michael H. Pillinger², ¹Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY, ²NYU School of Medicine, Division of Rheumatology, New York, NY, ³NYU School of Medicine, Division of Cardiology, New York, NY, ⁴Pediatric Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, ⁵Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, ⁶Internal Medicine, NYU School of Medicine, Department of Internal Medicine, New York, NY
Background/Purpose: Gout patients are at increased cardiovascular (CV) risk. Since atherosclerosis is an inflammatory process, anti-inflammatory strategies to reduce CV risk are currently being investigated.…
Abstract Number: 1912 • 2012 ACR/ARHP Annual Meeting
Colchicine, As Assessed by Target Joint Pain Scores, Is Effective At 16 Hours in Patients with Acute Gout Flares
Suman Wason¹, Thomas Lauterio¹, Steve Crockett¹ and Matthew W. Davis², ¹Clinical Development, URL Pharma, Philadelphia, PA, ²Clinical Pharmacology, URL Pharma, Philadelphia, PA
Background/Purpose: The management of patients with gout remains suboptimal, leading to increasing frequency and severity of recurrent flares that eventually lead to joint destruction and…
Abstract Number: 747 • 2012 ACR/ARHP Annual Meeting
Familial Mediterranean Fever: Inhibition of IL-6 Signalling As a New Therapeutic Option in a Frequent Autoinflammatory Syndrome.
Nicola Stein¹, Matthias Witt², Michael Baeuerle³, Fabian Proft¹, Hendrik Schulze-Koops⁴ and Mathias Gruenke¹, ¹Rheumaeinheit, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany, ²Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ³Division of Rheumatology, Klinikum Nürnberg, Nuernberg, Germany, ⁴University of Munich, Munich, Germany
Background/Purpose: Familial Mediterranean Fever (FMF) is the most prevalent episodic fever syndrome with more than 100.000 affected individuals worldwide. Colchicine is the established first-line therapy…
Abstract Number: 138 • 2012 ACR/ARHP Annual Meeting
Evaluating Appropriate Use of Prophylactic Colchicine and Urate Lowering Therapy in Gout
Michael George¹, Sally W. Pullman-Mooar² and H. Ralph Schumacher³, ¹Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania and Philadelphia Veterans Hospital, Philadelphia, PA, ³Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA
Background/Purpose: Colchicine is recommended to prevent gout flares in patients initiating and increasing uric acid lowering therapy until serum uric acid is ≤ 6 mg/dL.…
Abstract Number: 141 • 2012 ACR/ARHP Annual Meeting
Effectiveness of Prophylaxis with Anti-Gout Medications On Risk of Gout Attacks
Tuhina Neogi¹, Clara Chen², Jingbo Niu³, Christine E. Chaisson⁴, David J. Hunter⁵, Hyon Choi⁶ and Yuqing Zhang⁷, ¹Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Boston University School of Medicine, Boston, MA, ⁴Arthritis Center, Boston University School of Public Health, Boston, MA, ⁵Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ⁶Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁷Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: While a few studies have examined colchicine's ability to prevent gout attacks, NSAIDs have not been formally studied in this regard, despite use of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].